Key Points Viking is testing weight loss drug candidates in late-stage trials. The company recently showed that weight loss lasts after taking its drug candidate. 10 stocks we like better than Viking Therapeutics › Today, a very valuable market -- one heading toward $100 billion by the end of the decade -- is dominated by two pharma giants, Eli Lilly and Novo Nordisk . And this is the weight loss drug market. Lilly and Novo each sell GLP-1 drugs, products that have seen soaring demand and have delivered blockbuster revenue. But a new potential player is waiting in the wings and has been taking important steps forward.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.